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Urinary exosomes
Exosomes in human urine would exclusively derive from each 
cell type of the urinary tract starting from the glomerular 
podocytes and the kidney (1-3). In fact, the glomerular 
filtration apparatus apparently prevents blood-borne vesicles 
from entering the nephron (4). Exosomes in the urinary tract 
can play a cell-signaling role. For example, exosomes released 
by collecting duct cells induce the expression of aquaporin in 
recipient cells (5) and stimulate nephrogenesis (6). Exosomes 
can also simply cross the whole urinary tract being ultimately 
found in the urine. Being cell type specific, especially the 
urinary exosomes are a biomarker source for cancer diagnosis 
(2,7) and also for diseases of the urinary tract (8). The protein 
content of exosomes conveyed into urine is specific (9), being 
even representative of the expression levels (10) within the cell 
of origin.
The exosomal urinary proteome has been catalogued (11). 
The most recent version of the exosome database, Exocarta 
(Version 4), reports that exosomes from a variety of cell 
sources have been found to contain 4,563 proteins, 194 
lipids, 1,639 mRNAs, and 764 micro (mi)RNAs (12). 
Micro RNAs are small, non-coding RNAs that post-
transcriptionally inhibit gene expression and are therefore 
important players in exosome key functions (13). Exosomes 
also contain DNA and functional long non-coding RNAs 
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(lncRNAs) which may induce cancer-like phenotypes (14). 
We previously conducted a proteomic analysis of urinary 
exosomes by Orbitrap mass spectrometry, and compared it 
to urinome (15,16). It was found that most proteins in the 
urinome are in exosomes. Moreover, a consistent number 
of the identified proteins unexpectedly clustered to aerobic 
ATP production. Cytoscape software analysis allowed us to 
assess that most of their gene name signature was associated 
with aerobic glucose metabolism (15). In fact, similarly to 
human exosomes from umbilical cord MSC (17), urinary 
exosomes consumed oxygen to aerobically synthesize ATP (15).
Exosome composition and biogenesis
Exosomes are membrane-derived vesicles of 30–100 nm, 
shed from several types of cells (12,18) especially malignant 
ones (19). Exosomes are found in consistent concentrations 
in all body fluids, including blood, saliva and urine (20-22). 
Exosomes promote intercellular exchange of molecular 
information in physiological and pathological processes, 
including inflammation and cancer (23-25). Exosomes carry 
a variety of proteins, DNA and RNA molecules (25) and 
lipids, among which glycerophospholipids, sphingolipids, 
and especially cholesterol (8), but also eicosanoids. The 
latter are involved in tumor growth but also its prevention: 
exosomal docosahexaenoic acid promotes dendritic cell 
function (26).
Exosome biogenesis and the processes involved in 
the selection, packaging, and release of its cargo remain 
undefined. The endosomal sorting complex required for 
transport (ESCRT) is involved in exosome formation, but 
a key role was found for syndecan-syntenin-ALIX (27). 
A regulatory role for heparan sulfate in exosome 
production/secretion was proposed, as overexpression of 
the endoglycosidase enzyme heparanase increased tumor 
cell exosome secretion (28). Sequence motifs present in 
miRNAs are involved in their sorting into exosomes (29). 
Exosome protein content depends on the cell of origin, 
being enriched with fusion proteins, heat shock proteins, 
membrane trafficking proteins (Rab proteins), cytoplasmic 
enzymes, and the cited functional redox chain complexes I 
to V (15,17). Incompletely understood is the mechanisms 
underlying the sorting of proteins into exosomes. This topic 
is the object of several studies, which unfortunately yet 
have not addressed the key point of how can mitochondrial 
proteins be part of the exosome. Considering the complex 
assembly of the mitochondrial redox chains (30) inside 
the inner mitochondrial membranes (IMMs), and absence 
of contact with mitochondria during the exosome 
biogenesis, conceivably the redox chain proteins must 
already part of the endosomal membrane from which 
exosomes bud (31). A fusion of IMM with the endoplasmic 
reticulum (ER) was reported (23). There is a phospholipid 
exchange among IMM and the ER (32) also through the 
mitochondria associated membranes (33). The exosome 
release mechanism remains elusive; it was proposed to be 
Ca2+-dependent, and in some tumor cells Rab GTPase-
dependent (25). Exosomes interact with target cells mostly 
by endocytosis but also plasma membrane fusion (34). It was 
postulated that mesenchymal stem cells (MSCs) exosomes 
can carry out protein complementation of biochemically 
active enzymes (35) to correct cellular ATP deficit (36,37). 
It is tempting to presume that among these enzymes there 
are the exosomal redox chains proteins (15,17).
Urinary exosomes in cancer biology
The role of exosomes in cancer biology is an active area of 
investigation. Compared to healthy cells, tumor cells secrete 
a higher amount of exosomes (19,38), that are implied 
in tumorigenesis (39). Exosomes were shown to enhance 
migration, invasion and angiogenesis in bladder, prostate 
and renal cancer (38). Cancer cell support the cancer 
micro-environment of neighboring cells (40), through 
establishing a pre-metastatic niche (19,41), assisting the 
tumor in immune evasion and reprogramming of fibroblasts 
to myofibroblasts (42). Urinary exosomes possess oncogenic 
properties, including the promotion of cell migration and 
angiogenesis, blockade of apoptosis and of immunity (38).
Renal cell carcinoma (RCC)
RCC accounts for 3% of human malignancies. If localized 
RCC is often curable by surgery. However, only 12% 
patients with metastatic RCC are alive at 5 years. In search 
for biomarkers that are particularly needed for this type of 
cancer, a comparative proteomics was conducted on urinary 
exosomes isolated from urines of RCC patient compared 
with control subjects (43). This study has shown that RCC 
exosome protein content is substantially and reproducibly 
different from control UE. Interestingly, among the proteins 
that are not shared between RCC and control exosomes 
are those involved in matrix remodeling, over-expressed in 
RCC patients (43). RCC also possess a population of cancer 
stem cells (CSCs) that secrete large amount of extracellular 
vesicles that correlated with the disease progression and the 
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metastatic potential (44) promoting tumor cell development 
and vascularization. Since endothelial cells are critical for 
angiogenesis and tumor metastasis, their recruitment by 
cancer cells appears extremely interesting (44).
Bladder cancer
High-grade bladder cancer is associated to high mortality 
rates. The role of human bladder cancer cell-derived 
exosomes on tumor cells viability was addressed in a study 
utilizing exosomes purified from the supernatants of 
bladder cancer T24 cell cultures. This study demonstrated 
that bladder cancer cell-derived exosomes inhibited tumor 
cell apoptosis in bladder-cancer lines (45). Exosomes from 
human bladder cancer cell lines (TCC-SUP) and urine 
of patients with high grade bladder cancer were found to 
promote angiogenesis and migration of bladder cancer cells. 
In particular, EDIL-3 was found to facilitate angiogenesis, 
and urothelial and endothelial cell migration. Consistently, 
exosomes purified from the urine of patients with high 
grade bladder cancer contained significantly higher EDIL-3 
levels than healthy controls (46). The evidence that bladder 
cancer-derived exosomes affect bladder cancer progression, 
allows hypothesizing that targeting excretion and survival of 
exosomes can lead to novel therapeutic treatment strategies 
for this kind of cancer.
Prostate cancer
New biomarkers are needed for the diagnosis of prostate 
cancer, especially for the low-risk group (47). In fact, 
PSA lacks specificity and sensitivity. It was reported that 
urine collected after prostate massage contain exosomes 
secreted from prostate cancer cells (48). By next generation 
sequencing, the miRNA expression in a cohort of prostate 
cancer patients versus controls was studied. It was 
found that miRNA isoforms (isomiR-21, -204 and -375) 
with 3’ end modifications were highly discriminatory 
between control and affected men, with a high diagnostic 
performance. Proteins form exosomes isolated from urine 
after massage were analyzed by LC-MS/MS and it was 
found that eleven proteins were increased in patients with 
prostate cancer, compared to those with negative biopsy. In 
particular, fatty acid binding protein 5 (FABP5) appeared 
to be the best potential biomarker to predict high-grade 
(Gleason score >7) prostate cancer. Interestingly, not 
only exosomal proteins and miRNA have a discriminative 
potential in prostate cancer, but also exosomal lipids. Their 
content appears to be significantly different among patients 
and controls (24). Lipid identification in urine exosomes as 
prostate cancer biomarkers can be envisaged. Notably, the 
cargos of exosomes are associated alto to the tumor growth, 
metastasis and drug resistance of prostate cancer. prostate 
cancer cells exosomes modulate surrounding stromal 
cells modulating microenvironment (47). This allows to 
foresee that in the next future urinary exosomes may carry 
discriminatory information which is useful to generate 
stronger biomarkers.
Urine as a privileged tool for liquid biopsy
In the field of precision medicine, the development of a non-
invasive “liquid biopsy” represents a significant innovation, 
having the potential to reduce tumor biopsies. In urologic 
cancers, liquid biopsy is a privileged non-invasive tool for 
biomarker discovery (49). Liquid biopsies can be analyzed by 
high-throughput technologies at the cellular, circulating cell-
free DNA (cfDNA), RNA, exosome and metabolome levels 
as a source for tumor-derived information (49). Analysis 
of the urine is particularly promising for urinary tract 
malignancies (2,4). In addition to the importance of markers 
of cancer in urinary exosomes, finding markers of kidney 
failure would also be important, as most kidney and urinary 
tract diseases have a late clinical presentation.
Urine is a known source for biomarkers in various urinary 
tract cancers, such as bladder, kidney and prostate (4,6). In 
order to harness the potential usefulness of urinary exosomes 
in cancer, standardization of the isolation method among 
the laboratories is going to be a fundamental topic. For 
example, isolation can be performed by ultracentrifugation or 
by double-filtration microfluidics. A recent report in which 
exosomes were isolated from urine by an integrated double-
filtration microfluidic system found that the concentration of 
urinary exosomes was significantly higher in bladder cancer 
patients than in healthy controls (50).
With respect to blood-based biomarkers, for which a major 
challenge remains the possibility to contextualize peripheral 
markers to the complex tumor microenvironment, urine 
exosomes appear more focused to it, as they would come 
from relatively near cancer tissues moreover sharing a 
common embryonal origin. In this respect, urine exosomes 
can better allow to detect membrane proteins from the 
tumor. In fact, we have previously shown that most urinary 
proteins occur in the exosomes and these preserve them 
more efficiently than in total urine, a challenging fluid (15). 
Moreover, as the metabolic ability of the exosomes seems to 
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reflect that the cell of origin (17), it can be envisaged that 
one more biomarker may be searched for, particularly in 
urine that represent an unlimited source of exosomes.
Although urine exosome analysis as a source for biomarker 
proteins in search for renal and urinary tract tumors still 
needs validation to be transferred to clinical practice, it 
represents the logical extension of personalized medicine 
intended to tailor treatment to the individual. The perspective 
to have powerful tool to identify reliable prognostic and 
predictive biomarker for the diagnosis and tailored therapy 
specific urinary tract cancers appears particularly promising 




Conflicts of Interest: The author has no conflicts of interest to 
declare.
References
1. Dear JW, Street JM, Bailey MA. Urinary exosomes: A 
reservoir for biomarker discovery and potential mediators 
of intrarenal signalling. Proteomics 2013;13:1572-80.
2. Gámez-Valero A, Lozano-Ramos SI, Bancu I, et al. 
Urinary Extracellular Vesicles as Source of Biomarkers in 
Kidney Diseases. Front Immunol 2015;6:6.
3. Bourderioux M, Nguyen-Khoa T, Chhuon C, et al. A 
new workflow for proteomic analysis of urinary exosomes 
and assessment in cystinuria patients. J Proteome Res 
2015;14:567-77.
4. Pisitkun T, Johnstone R, Knepper MA. Discovery of 
urinary biomarkers. Mol Cell Proteomics 2006;5:1760-71.
5. Street JM, Birkhoff W, Menzies RI, et al. Exosomal 
transmission of functional aquaporin 2 in kidney cortical 
collecting duct cells. J Physiol 2011;589:6119-27.
6. Quandt D, Dieter Zucht H, Amann A, et al. Implementing 
liquid biopsies into clinical decision making for cancer 
immunotherapy. Oncotarget 2017;8:48507-20.
7. Moon PG, You S, Lee JE, et al. Urinary exosomes and 
proteomics. Mass Spectrom Rev 2011;30:1185-202.
8. Lin J, Li J, Huang B, et al. Exosomes: Novel Biomarkers 
for Clinical Diagnosis. ScientificWorldJournal 
2015;2015:657086.
9. Dimov I, Jankovic Velickovic L, Stefanovic V. Urinary 
exosomes. ScientificWorldJournal 2009;9:1107-18.
10. Hogan MC, Johnson KL, Zenka RM, et al. 
Subfractionation, characterization, and in-depth proteomic 
analysis of glomerular membrane vesicles in human urine. 
Kidney Int 2014;85:1225-37.
11. Conde-Vancells J, Rodriguez-Suarez E, Embade N, et al. 
Characterization and comprehensive proteome profiling 
of exosomes secreted by hepatocytes. J Proteome Res 
2008;7:5157-66.
12. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular 
organelles important in intercellular communication. J 
Proteomics 2010;73:1907-20.
13. Kosaka N, Yoshioka Y, Hagiwara K, et al. Trash or 
Treasure: extracellular microRNAs and cell-to-cell 
communication. Front Genet 2013;4:173.
14. Gezer U, Özgür E, Cetinkaya M, et al. Long non-coding 
RNAs with low expression levels in cells are enriched in 
secreted exosomes. Cell Biol Int 2014;38:1076-9.
15. Bruschi M, Santucci L, Ravera S, et al. Human urinary 
exosome proteome unveils its aerobic respiratory ability. J 
Proteomics 2016;136:25-34.
16. Bruschi M, Ravera S, Santucci L, et al. Human urinary 
exosome as a metabolic effector cargo. Expert Rev 
Proteomics 2015;12:425-32.
17. Panfoli I, Ravera S, Podestà M, et al. Exosomes from 
human mesenchymal stem cells conduct aerobic 
metabolism in term and preterm newborn infants. FASEB 
J 2016;30:1416-24.
18. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, 
microvesicles, and friends. J Cell Biol 2013;200:373-83.
19. Kharaziha P, Ceder S, Li Q, et al. Tumor cell-derived 
exosomes: a message in a bottle. Biochim Biophys Acta 
2012;1826:103-11.
20. Vlassov AV, Magdaleno S, Setterquist R, et al. Exosomes: 
current knowledge of their composition, biological 
functions, and diagnostic and therapeutic potentials. 
Biochim Biophys Acta 2012;1820:940-8.
21. Wang D, Sun W. Urinary extracellular microvesicles: 
isolation methods and prospects for urinary proteome. 
Proteomics 2014;14:1922-32.
22. Lässer C, Alikhani VS, Ekström K, et al. Human saliva, 
plasma and breast milk exosomes contain RNA: uptake by 
macrophages. J Transl Med 2011;9:9.
23. Clayton A, Al-Taei S, Webber J, et al. Cancer exosomes 
express CD39 and CD73, which suppress T cells through 
adenosine production. J Immunol 2011;187:676-83.
24. Llorente A, Skotland T, Sylvänne T, et al. Molecular 
lipidomics of exosomes released by PC-3 prostate cancer 
S1393Translational Cancer Research, Vol 6, Suppl 8 October 2017
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2017;6(Suppl 8):S1389-S1393 tcr.amegroups.com
cells. Biochim Biophys Acta 2013;1831:1302-9.
25. H Rashed M, Bayraktar E, K Helal G, et al. Exosomes: 
From Garbage Bins to Promising Therapeutic Targets. Int 
J Mol Sci 2017;18: pii: E538.
26. Pitt JM, Charrier M, Viaud S, et al. Dendritic Cell-
Derived Exosomes as Immunotherapies in the Fight 
against Cancer. J Immunol 2014;193:1006-11.
27. Baietti MF, Zhang Z, Mortier E, et al. Syndecan-syntenin-
ALIX regulates the biogenesis of exosomes. Nat Cell Biol 
2012;14:677-85.
28. Thompson CA, Purushothaman A, Ramani VC, et 
al. Heparanase regulates secretion, composition, and 
function of tumor cell-derived exosomes. J Biol Chem 
2013;288:10093-9.
29. Zhang J, Li S, Li L, et al. Exosome and Exosomal 
MicroRNA: Trafficking, Sorting, and Function. Genomics 
Proteomics Bioinformatics 2015;13:17-24.
30. Genova ML, Baracca A, Biondi A, et al. Is supercomplex 
organization of the respiratory chain required for 
optimal electron transfer activity? Biochim Biophys Acta 
2008;1777:740-6.
31. Panfoli I, Ravera S, Bruschi M, et al. Proteomics unravels 
the exportability of mitochondrial respiratory chains. 
Expert Rev Proteomics 2011;8:231-9. 
32. Lebiedzinska M, Szabadkai G, Jones AW, et al. Interactions 
between the endoplasmic reticulum, mitochondria, plasma 
membrane and other subcellular organelles. Int J Biochem 
Cell Biol 2009;41:1805-16.
33. Raturi A, Simmen T. Where the endoplasmic reticulum 
and the mitochondrion tie the knot: the mitochondria-
associated membrane (MAM). Biochim Biophys Acta 
2013;1833:213-24.
34. Cocucci E, Meldolesi J. Ectosomes and exosomes: 
shedding the confusion between extracellular vesicles. 
Trends Cell Biol 2015;25:364-72.
35. Lai RC, Yeo RW, Tan KH, et al. Mesenchymal stem cell 
exosome ameliorates reperfusion injury through proteomic 
complementation. Regen Med 2013;8:197-209.
36. Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem 
cell-derived exosomes increase ATP levels, decrease 
oxidative stress and activate PI3K/Akt pathway to enhance 
myocardial viability and prevent adverse remodeling after 
myocardial ischemia/reperfusion injury. Stem Cell Res 
2013;10:301-12.
37. Lai RC, Yeo RW, Lim SK. Mesenchymal stem cell 
exosomes. Semin Cell Dev Biol 2015;40:82-8.
38. Franzen CA, Blackwell RH, Foreman KE, et al. Urinary 
Exosomes: The Potential for Biomarker Utility, 
Intercellular Signaling and Therapeutics in Urological 
Malignancy. J Urol 2016;195:1331-9.
39. Zhang X, Yuan X, Shi H, et al. Exosomes in cancer: small 
particle, big player. J Hematol Oncol 2015;8:83.
40. Hanahan D, Weinberg RA. Hallmarks of cancer: The next 
generation. Cell 2011;144:646-74.
41. Rabinowits G, Gerçel-Taylor C, Day JM, et al. Exosomal 
microRNA: a diagnostic marker for lung cancer. Clin 
Lung Cancer 2009;10:42-6.
42. Maas SLN, Breakefield XO, Weaver AM. Extracellular 
Vesicles: Unique Intercellular Delivery Vehicles. Trends 
Cell Biol 2017;27:172-88. 
43. Raimondo F, Morosi L, Corbetta S, et al. Differential 
protein profiling of renal cell carcinoma urinary exosomes. 
Mol Biosyst 2013;9:1220.
44. Lindoso RS, Collino F, Camussi G, et al. Extracellular 
vesicles derived from renal cancer stem cells induce a pro-
tumorigenic phenotype in mesenchymal stromal cells. 
Oncotarget 2015;6:7959-69.
45. Yang L, Wu XH, Wang D, et al. Bladder cancer cell-
derived exosomes inhibit tumor cell apoptosis and induce 
cell proliferation in vitro. Mol Med Rep 2013;8:1272-8.
46. Beckham CJ, Olsen J, Yin PN, et al. Bladder Cancer 
Exosomes Contain EDIL-3/Del1 and Facilitate Cancer 
Progression. J Urol 2014;192:583-92.
47. Pan J, Ding M, Xu K, et al. Exosomes in diagnosis and 
therapy of prostate cancer. Oncotarget 2015;5:1-8.
48. Zijlstra C, Stoorvogel W. Prostasomes as a source of 
diagnostic biomarkers for prostate cancer. J Clin Invest 
2016;126:1144-51.
49. Di Meo A, Bartlett J, Cheng Y, et al. Liquid biopsy: a 
step forward towards precision medicine in urologic 
malignancies. Mol Cancer 2017;16:80.
50. Liang LG, Kong MQ, Zhou S, et al. An integrated double-
filtration microfluidic device for isolation, enrichment and 
quantification of urinary extracellular vesicles for detection 
of bladder cancer. Sci Rep 2017;7:46224.
Cite this article as: Panfoli I. Cancer exosomes in urine: a 
promising biomarker source. Transl Cancer Res 2017;6(Suppl 
8):S1389-S1393. doi: 10.21037/tcr.2017.10.17
